Attorney Docket No.: MBM1200 In Re Application of: Steeves et al.

Application Serial No.: 09/530,234 Filed: July 6, 2000

Page 2

**AMENDMENT** 

In the Claims

Please cancel claims 55-57 and 62-64 without prejudice and amend claims 46, 58, and

60 as set forth below. Upon entry of the amendments, the status of the claims will be as

follows:

(Currently Amended) A method for promoting neuron repair or regeneration in a 46.

human subject suffering from spinal cord disruption by the transient disruption of myelin or

transient demyelination, comprising administering intrathecal administration of a

therapeutically effective amount of a composition comprising:

one or more complement-fixing antibodies or fragments thereof, which (a)

specifically bind to galactocerebroside (GalC); and

one or more complement proteins or fragments thereof, wherein at least (b)

one of the complement proteins is a C3 protein;

wherein the combination of said antibodies and complement proteins causes activation of the

complement system resulting in disruption of myelin or demyelination, thereby promoting

neuron repair or regeneration.

Claims 47-57 (Canceled)

(Currently Amended) The method according to claim 46, wherein the antibodies are an 58.

immunoreactive fragment selected from the group consisting of Fv, Fab, Fab', or and F(ab')2

fragments.

GT\6436242.1

In Re Application of: Steeves et al. Attorney Docket No.: MBM1200

Application Serial No.: 09/530,234

Filed: July 6, 2000

Page 3

59. (Previously Presented) The method according to claim 58, wherein the variable regions of the Fv fragment are linked by disulfide bonds or by a peptide linker.

- 60. (Currently Amended) The method according to claim 46, wherein the neuron dysfunction spinal cord disruption is caused by injury or trauma to the CNS.
- 61. (Previously Presented) The method according to claim 60, wherein the injury is a spinal cord injury.

62-64 (Cancelled).